Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23015
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Metser, Ur | - |
dc.contributor.author | Chua, Sue | - |
dc.contributor.author | Ho, Bao | - |
dc.contributor.author | Punwani, Shonit | - |
dc.contributor.author | Johnston, Edward | - |
dc.contributor.author | Pouliot, Frederic | - |
dc.contributor.author | Tau, Noam | - |
dc.contributor.author | Hawsawy, Asmaa | - |
dc.contributor.author | Anconina, Reut | - |
dc.contributor.author | Bauman, Glenn | - |
dc.contributor.author | Hicks, Rodney J | - |
dc.contributor.author | Weickhardt, Andrew J | - |
dc.contributor.author | Davis, Ian D | - |
dc.contributor.author | Pond, Greg | - |
dc.contributor.author | Scott, Andrew M | - |
dc.contributor.author | Tunariu, Nina | - |
dc.contributor.author | Sidhu, Harbir | - |
dc.contributor.author | Emmett, Louise | - |
dc.date | 2019-03-22 | - |
dc.date.accessioned | 2020-04-17T00:40:16Z | - |
dc.date.available | 2020-04-17T00:40:16Z | - |
dc.date.issued | 2019-09 | - |
dc.identifier.citation | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019; 60(9): 1253-1258 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/23015 | - |
dc.description.abstract | Our purpose was to assess whether the addition of data from multiparametric pelvic MRI (mpMR) and whole-body MRI (wbMR) to the interpretation of 18F-fluoromethylcholine (18F-FCH) or 68Ga-HBED-CC PSMA-11 (68Ga-PSMA) PET/CT (=PET) improves the detection of local tumor recurrence or of nodal and distant metastases in patients after radical prostatectomy with biochemical failure. Methods: The current analysis was performed as part of a prospective, multicenter trial on 18F-FCH or 68Ga-PSMA PET, mpMR, and wbMR. Eligible men had an elevated level of prostate-specific antigen (PSA) (>0.2 ng/mL) and high-risk features (Gleason score > 7, PSA doubling time < 10 mo, or PSA > 1.0 ng/mL) with negative or equivocal conventional imaging results. PET was interpreted with mpMR and wbMR in consensus by 2 radiologists and compared with prospective interpretation of PET or MRI alone. Performance measures of each modality (PET, MRI, and PET/mpMR-wbMR) were compared for each radiotracer and each individual patient (for 18F-FCH, or 68Ga-PSMA for patients who had 68Ga-PSMA PET) and to a composite reference standard. Results: There were 86 patients with PET (18F-FCH [n = 76] and/or 68Ga-PSMA [n = 26]) who had mpMR and wbMR. Local tumor recurrence was detected in 20 of 76 (26.3%) on 18F-FCH PET/mpMR, versus 11 of 76 (14.5%) on 18F-FCH PET (P = 0.039), and in 11 of 26 (42.3%) on 68Ga-PSMA PET/mpMR, versus 6 of 26 (23.1%) on 68Ga-PSMA PET (P = 0.074). Per patient, PET/mpMR was more often positive for local tumor recurrence than PET (P = 0.039) or mpMR (P = 0.019). There were 20 of 86 patients (23.3%) with regional nodal metastases on both PET/wbMR and PET (P = 1.0) but only 12 of 86 (14%) on wbMR (P = 0.061). Similarly, there were more nonregional metastases detected on PET/wbMR than on PET (P = 0.683) or wbMR (P = 0.074), but these differences did not reach significance. Compared with the composite reference standard for the detection of disease beyond the prostatic fossa, PET/wbMR, PET, and wbMR had sensitivity of 50%, 50%, and 8.3%, respectively, and specificity of 97.1%, 97.1%, and 94.1%, respectively. Conclusion: Interpretation of PET/mpMR resulted in a higher detection rate for local tumor recurrence in the prostatic bed in men with biochemical failure after radical prostatectomy. However, the addition of wbMR to 18F-FCH or 68Ga-PSMA PET did not improve detection of regional or distant metastases. | - |
dc.language.iso | eng | - |
dc.subject | MR | - |
dc.subject | PET | - |
dc.subject | PSMA | - |
dc.subject | biochemical recurrence | - |
dc.subject | fluoromethylcholine | - |
dc.subject | Prostate cancer | - |
dc.title | The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. | - |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | - |
dc.identifier.affiliation | University of Toronto, Toronto, Canada. | - |
dc.identifier.affiliation | Université Laval, Quebec, Canada | en |
dc.identifier.affiliation | St. Vincent's Hospital, Sydney, Australia | en |
dc.identifier.affiliation | Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Peter MacCallum Cancer Centre, Melbourne, Australia | en |
dc.identifier.affiliation | Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia | en |
dc.identifier.affiliation | Royal Marsden Hospital, London, United Kingdom | - |
dc.identifier.affiliation | University College London, London, United Kingdom | - |
dc.identifier.affiliation | University of Toronto, Toronto, Canada | - |
dc.identifier.affiliation | London Health Sciences Centre, Ontario, Canada | - |
dc.identifier.affiliation | McMaster University, Hamilton, Ontario Canada | - |
dc.identifier.affiliation | Royal Marsden Hospital, London, United Kingdom.. | - |
dc.identifier.affiliation | University College London, London, United Kingdom | - |
dc.identifier.doi | 10.2967/jnumed.118.225185 | - |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-6656-295X | - |
dc.identifier.pubmedid | 30902875 | - |
dc.type.austin | Journal Article | - |
dc.type.austin | Multicenter Study | - |
dc.type.austin | Research Support, Non-U.S. Gov't | - |
local.name.researcher | Scott, Andrew M | |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.